The unveiling of Xenter’s new wireless guidewire product may provide significant competition to or potentially replace traditional guidewires in the transcatheter aortic valve replacement (TAVR) market. The TAVR market is growing substantially and is expected to be worth $6.8bn in 2023 and reach $18.8bn in 2033, according to GlobalData, a leading data and analytics company. Although guidewires make up a smaller portion of TAVR overall, this could have a noticeable impact on the future positions of Boston Scientific and Medtronic, which have products in this segment.

In the TAVR market, currently Boston Scientific and Medtronic currently occupy the guidewire space. Boston Scientific leads with its product, Safari 2, and Medtronic with its product, Confida. As a result of the clear advantages of implementing Xenter’s smart guidewire, the traditional guidewire could eventually be rendered obsolete, which may threaten both Boston Scientific’s and Medtronic’s TAVR market position. While Medtronic still produces revenue from other products in TAVR, a substantial portion of Boston Scientific’s TAVR revenue comes from guidewires and therefore this would put them in a riskier circumstance.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the increasing prevalence of aortic stenosis due to ageing populations and the general shift towards minimally invasive procedures, the demand for TAVR procedures is exponentially growing and will warrant more innovative methods to improve patient outcomes such as the wireless guidewire. As the market for TAVR procedures continues to grow, we may see companies begin to put out products such as Xenter’s guidewire to remain competitive.

Xenter’s first-of-its-kind dual sensor guidewire allows for the collection of real-time data points, which can provide an aortic regurgitation (AR) measurement and serve as a clinical decision support tool to improve the prediction of para valvular leak (PVL). PVL is a common concern for complications when it comes to TAVR procedures. New products that can aid in accurately predicting these outcomes will become increasingly important and may garner considerable interest from hospitals and healthcare practitioners.

While unveiling the smart guidewire may not immediately impact the TAVR market and more specifically Boston Scientific and Medtronic, it certainly has the potential to alter market positions if utilising this new technology becomes more commonplace for these medical procedures.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.